Compare 3M Company (MMM) vs Moderna, Inc. (MRNA) Price & Performance

3M (MMM) trades at $163.57, up 0.89% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with $2.40 EPS versus $2.25 expected, and raised full-year guidance. Revenue for 2025 was $24.95 billion with a net income margin of 11.9%, though profitability has moderated from prior years. Analysts maintain a consensus price target of $191.00, implying significant upside, with 48% recommending Buy.

The outlook for 3M is cautiously optimistic, driven by operational improvements and growth in industrial and electronics segments, but risks include high debt levels, weak consumer demand, and ongoing litigation costs. The stock's valuation at a P/E of 29.06 appears elevated relative to historical norms, requiring sustained earnings growth to justify further gains.

Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.

The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.